RT Journal Article
SR Electronic
T1 Antibody persistence and neutralising activity in primary school students and staff: prospective active surveillance, June to December 2020, England
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.14.21260502
DO 10.1101/2021.07.14.21260502
A1 Georgina Ireland
A1 Anna Jeffery-Smith
A1 Maria Zambon
A1 Katja Hoschler
A1 Ross Harris
A1 John Poh
A1 Frances Baawuah
A1 Joanne Beckmann
A1 Ifeanyichukwu O Okike
A1 Shazaad Ahmad
A1 Joanna Garstang
A1 Andrew J Brent
A1 Bernadette Brent
A1 Felicity Aiano
A1 Zahin Amin-Chowdhury
A1 Louise Letley
A1 Samuel E I Jones
A1 Meaghan Kall
A1 Monika Patel
A1 Robin Gopal
A1 Ray Borrow
A1 Ezra Linley
A1 Gayatri Amirthalingam
A1 Kevin E Brown
A1 Mary E Ramsay
A1 Shamez N Ladhani
YR 2021
UL http://medrxiv.org/content/early/2021/07/15/2021.07.14.21260502.abstract
AB Introduction SARS-CoV-2 serological studies have so far focused mainly on adults. Public Health England initiated prospective, longitudinal SARS-CoV-2 sero-surveillance in schools across England after the first national lockdown, which allowed comparison of child and adult responses to SARS-CoV-2 infection over time.Methods Staff and students had venepuncture for SARS-CoV-2 antibodies in school during June, July and December 2020. Blood samples were tested for nucleocapsid (Abbott) and receptor binding domain (RBD) antibodies (in-house assay), and student samples were additionally assessed for live virus neutralising activity.Results In June 2020, 1,344 staff and 835 students were tested. Overall, 11.5% (95% CI: 9.4-13.9) and 11.3% (95% CI: 9.2-13.6; p=0.88) of students had nucleoprotein and RBD antibodies, compared to 15.6% (95% CI: 13.7-17.6) and 15.3% (95% CI: 13.4-17.3; p=0.83) of staff. Live virus neutralising activity was detected in 79.8% (n=71/89) of nucleocapsid and 85.5% (71/83) of RBD antibody positive children. RBD antibodies correlated more strongly with neutralising antibodies (rs=0.7527; p<0.0001) than nucleocapsid antibodies (rs=0.3698; p<0.0001). A median of 24.4 weeks later, 58.2% (107/184) participants had nucleocapsid antibody seroreversion, compared to 20.9% (33/158) for RBD (p<0.001). Similar seroreversion rates were observed between staff and students for nucleocapsid (p=0.26) and RBD-antibodies (p=0.43). Nucleocapsid and RBD antibody quantitative results were significantly lower in staff compared to students (p=0.028 and <0.0001 respectively) at baseline, but not at 24 weeks (p=0.16 and p=0.37, respectively).Conclusion RBD antibodies correlated more strongly with live virus neutralising activity. Most seropositive students and staff retained RBD antibodies for >6 months after SARS-CoV-2 infection.Competing Interest StatementMR reports that The Immunisation and Countermeasures Division has provided vaccine manufacturers with post-marketing surveillance reports on pneumococcal and meningococcal infection which the companies are required to submit to the UK Licensing authority in compliance with their Risk Management Strategy. A cost recovery charge is made for these reports. AB reports that he is Chair of Governors of one of the schools included in the study. RB and EL reports other from GSK, other from Sanofi, other from Pfizer, outside the submitted work. All other authors have nothing to declare.Clinical Protocols https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/983299/sKIDs_protocol_v1.6.pdf Funding StatementUK Department of Health and Social CareAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The protocol was approved by PHE Research Ethics Governance Group (Ref: NR0209, 16 May 2020)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesApplications for relevant anonymised data should be submitted to the Public Health England Office for Data Release https://www.gov.uk/government/publications/accessing-public-health-england-data/about-the-phe-odr-and-accessing-data.